Procto-Glivenol rectal cream, 30 g in tubes with applicators.

In stock: 4
$65.00

Ingredients

Active ingredients: tribenoside, lidocaine hydrochloride;

100 g of cream contains 5 g of tribenoside and 2 g of lidocaine hydrochloride;

Inactive ingredients: polyethylene glycol cetostearyl ether, cetyl alcohol, isopropyl palmitate, mineral oil, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), sorbitol solution (E 420), stearic acid, sorbitan stearate, purified water.

Dosage Form

Rectal cream.

Main physical and chemical properties: a homogeneous white cream with a faint characteristic odor.

Pharmacotherapeutic group

Preparations for the treatment of hemorrhoids and anal fissures for topical use; combinations. ATC code C05A X03.

Pharmacological properties

Pharmacodynamics. 

Tribenoside belongs to the class of agents for the topical treatment of hemorrhoids. Tribenoside reduces capillary permeability and increases vascular tone; it also has anti-inflammatory properties. The drug’s antagonistic action targets certain endogenous substances that act as mediators in the development of inflammation and pain.

Lidocaine is a local anesthetic that relieves itching, burning, and pain caused by hemorrhoids.

Pharmacokinetics.

Absorption. The systemic bioavailability of tribenoside following rectal administration is only 30% of that achieved when the substance is administered orally or intravenously. Approximately 2–20% of the tribenoside contained in the rectal cream is absorbed through the skin. Maximum plasma concentrations of tribenoside and its metabolites are reached 2 hours after rectal administration of 400 mg of tribenoside and amount to 1 μg/mL.

Lidocaine is rapidly absorbed from the mucous membrane but is poorly absorbed from intact skin. The bioavailability of lidocaine following rectal administration is approximately 50%. The maximum plasma concentration of lidocaine is reached 112 minutes after rectal administration of 300 mg of lidocaine and is 0.70 μg/mL.

Distribution. Lidocaine is strongly bound to alpha-1-acid glycoprotein.

Metabolism. Tribenoside is actively metabolized in the body. Lidocaine is rapidly metabolized in the liver.

Excretion. Between 20% and 27% of a rectally administered dose of tribenoside is excreted in the urine as metabolites.

Lidocaine metabolites and less than 10% of unchanged lidocaine are excreted in the urine.

Indications

Topical treatment of external and internal hemorrhoids.

Contraindications

Hypersensitivity to any component of the drug, including amide-type local anesthetics.

Drug Interactions and Other Interactions

In patients taking Class 1 antiarrhythmic drugs (e.g., tocainide, mexiletine) or other local anesthetics should use this medication with caution, as there is a risk of cumulative systemic effects due to the presence of lidocaine. Monoamine oxidase inhibitors enhance the local anesthetic effect of lidocaine.

Special Considerations for Use

This medication should be used with caution in patients with severe heart failure, renal insufficiency, and hepatic insufficiency.

Patients are advised to consult a doctor if their condition does not improve after one week of use or if any other previously unobserved symptoms appear, in order to rule out other possible causes of these conditions.

In addition, when treating hemorrhoids with Procto-Glivenol, patients should follow recommendations regarding anal hygiene, an active lifestyle, and a healthy diet to ensure soft stools.

Procto-Glivenol rectal cream contains cetyl alcohol, which may cause local skin reactions (e.g., contact dermatitis), as well as methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).

The package contains a latex applicator for rectal administration of the cream. Latex can cause serious allergic reactions.

Avoid contact of the medication with the eyes.

Do not swallow the cream.

Use During Pregnancy or Breastfeeding

Pregnancy and breastfeeding.

No controlled studies have been conducted on the potential effects of tribenoside and lidocaine in pregnant or breastfeeding women. As a precaution, Procto-Glivenol rectal cream should not be used during the first trimester of pregnancy.

The medication may be used starting in the 4th month of pregnancy and by breastfeeding women, provided the recommended dosage is followed, taking into account the potential risk to both the mother and the child.

Fertility.

Studies show that lidocaine does not affect fertility.

There are no data on the potential effect of tribenoside on fertility.

Effect on reaction time when driving or operating machinery

The use of Procto-Glivenol has no or negligible effect on the ability to drive or operate machinery.

Dosage and Administration

For rectal use in adults.

Apply the rectal cream in the morning and evening until acute symptoms subside. After that, the cream may be applied once daily. The duration of treatment is determined by the doctor depending on the severity of the condition.

For internal hemorrhoids, apply the cream using the applicator tip, which is packaged separately and screws onto the tube. The applicator tip is covered with a protective cap, which must be removed before each application of the cream.

30 g of cream (1 tube) is sufficient for approximately 20–30 applications.

Children

Do not use in children, as there are no data on the use of this medication in this age group.

Overdose

There are no data on overdose with Procto-Glivenol. Overdose is not expected if the medication is used according to the dosing schedule.

In animal studies, lidocaine overdose was associated with effects on the central nervous and cardiovascular systems.

In case of accidental ingestion, gastric lavage should be performed promptly, and medical attention should be sought. There is no specific antidote for lidocaine.

Side Effects

Rare adverse reactions reported during treatment include local reactions such as burning, pain, rash, and itching, which may spread beyond the application site. In addition to these adverse effects, the administration of Procto-Glivenol rectal cream may, in very rare cases, cause an anaphylactic reaction, including symptoms such as angioedema and facial swelling.

List of Adverse Reactions.

Adverse reactions are listed below by system organ class according to MedDRA. Frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000) or unknown (cannot be estimated from the available data). Within each frequency group, adverse reactions are listed in order of decreasing severity.

Immune system disorders 
Very rare Anaphylactic reactions
Cardiac
Very rare Cardiovascular disorders
Respiratory, thoracic, and mediastinal disorders
Very rare Bronchospasm
Skin and subcutaneous tissue disorders
Rare Urticaria, contact dermatitis
Very rare Quincke’s edema
General complications and reactions at the application site
Rare Discomfort, mild burning sensation, itching, rash, pain at the application site
Very rare Facial swelling, fever, hemorrhoidal bleeding

Given that lidocaine is rapidly absorbed through the mucous membranes, systemic effects may occur.

Shelf life

3 years.

Storage conditions

Keep out of reach of children.

Store at a temperature not exceeding 25 °C.

Packaging

30 g of cream per tube; 1 tube per pack, complete with an applicator, in a cardboard box.

Dispensing Category

Over-the-counter.